What is the appropriate intravenous artesunate dosing for a 61‑kg, 40‑year‑old patient?

Intravenous Artesunate Dosing for 61 kg, 40-Year-Old Patient

For a 61 kg patient, administer intravenous artesunate at 2.4 mg/kg, which equals 146.4 mg (approximately 1.3 vials of 110 mg each), given at 0,12, and 24 hours, then continue with 2.4 mg/kg daily for up to 7 days depending on clinical response. 1

Dosing Algorithm

Initial Intensive Phase (First 24 Hours)

• Dose calculation: 2.4 mg/kg × 61 kg = 146.4 mg per dose
• Timing: Administer at 0 hours (immediately), 12 hours, and 24 hours
• Practical preparation: Use 2 vials (220 mg total) and discard excess, or precisely measure 1.33 vials

Continuation Phase (After 24 Hours)

The continuation depends on two clinical parameters:

If patient can take oral medication AND parasitemia <1%:

• Switch to a complete oral artemisinin-based combination therapy regimen (preferably dihydroartemisinin-piperaquine or artemether-lumefantrine) 1

If patient cannot take oral medication OR parasitemia ≥1%:

• Continue IV artesunate at 2.4 mg/kg (146.4 mg) once daily for up to 7 days total 1

Key Clinical Considerations

Administration Details

• Artesunate comes as 110 mg vials 1
• Administer as slow IV injection or infusion (not intramuscular)
• This is first-line treatment for severe/complicated malaria of all species 1

Critical Monitoring

Monitor for post-artesunate delayed hemolysis (PADH), which can occur even after successful parasite clearance 1. This is the most important adverse effect and requires:

• Serial hemoglobin/hematocrit monitoring for at least 4 weeks post-treatment
• Particular vigilance in patients with high initial parasitemia

Common Pitfalls to Avoid

1. Underdosing in heavier patients: Don't round down—this 61 kg patient needs the full 146.4 mg, not just 1 vial (110 mg)

2. Premature switch to oral therapy: Ensure both criteria are met (oral tolerance AND parasitemia <1%) before transitioning 1

3. Incomplete treatment course: If continuing IV therapy beyond 24 hours, don't forget the daily maintenance doses—incomplete treatment risks treatment failure

4. Missing the transition point: Reassess at 24 hours to determine whether to continue IV or switch to oral therapy based on clinical status and parasitemia

Evidence Quality Note

The 2024 Clinical Microbiology and Infection guidelines 1 represent the most current expert consensus and are endorsed by WHO, European, and North American guidelines. The 2.4 mg/kg dosing has been validated in multiple clinical studies, including the U.S. CDC experience with over 100 patients showing 6.9% mortality and good safety profile 2.